

> 


# CARDIAC RHYTHM MANAGEMENT DEVICES

![](https://i.imgur.com/e60Enm5.jpg)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Common Pacing Modes</b></p></td></tr><tr><td><p><b>VVI</b></p></td><td><p>Ventricular pacing on demand with single lead in RV. Sensed ventricular beat</p><p>inhibits V pacing. Used in chronic AF with symptomatic bradycardia.</p></td></tr><tr><td><p><b>DDD</b></p></td><td><p>A &amp; V sensing/pacing (RA &amp; RV leads). Native A beat inhib A pacing &amp; <i>triggers</i></p><p><i>V pacing</i> → tracking of intrinsic atrial activity. Maintains AV synchrony, ↓ AF.</p></td></tr><tr><td><p><b>Mode Switch</b></p></td><td><p>In atrial tachyarrhythmia (eg, AF), PPM ∆s from DDD to nontracking mode (eg, VVI). Prevents PPM from pacing at max V rate in response to rapid atrial rate.</p></td></tr><tr><td><p><b>Magnet</b> over generator</p></td><td><p>PPM: fixed rate pacing (VOO/DOO). ICD: no shock, pacing preserved.</p><p>Indic: ✔ capture; surgery; inapprop PPM inhib/ICD shock, PM-mediated tachy</p></td></tr><tr><td colspan="2"><p><i>Leadless</i> intracardiac PPM approved for single chamber RV pacing (<span><i>Circ</i> 2017;135:1458</span>); His bundle pacing ↓ death/HF/CRT upgrade vs RV pacing alone (<span><i>JACC</i> 2018;71:2319</span>).</p></td></tr></tbody></table>

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Indications for Permanent Pacing</b> (<span><i>Circ</i> 2008;117:350 &amp; 2012;126:1784</span>)</p></td></tr><tr><td><p><b>AV block</b></p></td><td><p>3° or type II 2° AVB a/w sx or with either HR &lt;40 or asystole ≥3 sec (≥5 if in AF) while awake; ? asx 3° or type II 2° AVB; bifasc or alter. L &amp; R BBB</p></td></tr><tr><td><p><b>Sinus node</b></p></td><td><p>SB, pauses (SSS), chronotrop incompet a/w sx or ? if sx without clear assoc</p></td></tr><tr><td><p><b>Tachy-arrhythmia</b></p></td><td><p>AF with SSS; sx recurrent SVT term. by pacing after failing drugs/ablation; Sustained pause-dependent VT; ? high-risk congenital long QT</p></td></tr><tr><td><p><b>Syncope</b></p></td><td><p>Carotid sinus hypersensitivity with asystole &gt;3 sec</p><p>? Neurocardiogenic syncope with prominent cardioinhib. response</p><p>? Syncope with bi- or trifascicular block and not likely 2° to other causes</p></td></tr></tbody></table>

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Pacemaker Complications</b></p></td></tr><tr><td><p><b>Issue</b></p></td><td><p><b>Manifestation</b></p></td><td><p><b>Description &amp; 原因</b></p></td></tr><tr><td><p>Perforation</p></td><td><p>Effusion/tamp/pain</p></td><td><p>Typically acute, consider if HoTN</p></td></tr><tr><td><p>Failure to pace</p></td><td><p>Bradycardia</p></td><td><p>↓ Battery, lead fx/dislodgment, ↑ pacing threshold due to tissue rxn/injury; oversense → inapprop. inhib</p></td></tr><tr><td><p>Failure to sense</p></td><td><p>Inapprop. pacing</p></td><td><p>Lead dislodgment or sensing threshold too high</p></td></tr><tr><td><p>PM-mediated tachycardia</p></td><td><p>WCT at device upper rate</p></td><td><p>Seen with DDD. V → A retrograde conduction; sensed by A lead → triggers V pacing → etc.</p></td></tr><tr><td><p>PM syndrome</p></td><td><p>Palpit, HF</p></td><td><p>Seen with VVI, due to loss of AV synchrony</p></td></tr></tbody></table>

### Cardiac resynch therapy (CRT)/Biventricular (BiV) pacing (_JACC_ 2013;61:e6)

• 3-lead pacemaker (RA, RV, coronary sinus to LV); R > S in V1 suggests approp LV capture

• Synch LV fxn (↑ CO/EF, ↓ adv remodeling); ↓ HF sx & hosp, ↑ survival (_NEJM_ 2010;363:2385)

• **Indications:** LVEF ≤35% + NYHA II–IV despite med Rx + SR + LBBB ≥150 ms (also reasonable if LBBB ≥120 ms, any non-LBBB ≥150 ms, or >40% V-pacing); mort. benefit with CRT-D only if LBBB (& QRS ≥130ms) (_NEJM_ 2014;370:1694)

? benefit in NYHA I–III, EF ≤50% with PPM indication for AVB (_NEJM_ 2013;368:1585)

### Implantable cardiac defibrillator (ICD) (_JACC_ 2013;61:e6; _Circ_ 2015;132:1613)

• RV lead: defib & pacing (± antitachycardia pacing \[ATP\] = burst pacing > VT rate to stop VT); ± RA lead for dual-chamber PPM. Subcut-ICD (consider if young), but ∅ pace/ATP.

• **Pt selection** (_JACC_ 2008;51:e1; _Circ_ 2012;126:1784)

2° prev: survivors of VT/VF arrest without revers cause; asx sustained VT + struct. heart dis.

1° prevention: LVEF ≤30% & post-MI _or_ LVEF ≤35% & NYHA II–III (wait: ≥40 d if post-MI, ≥90 d for niCMP) _or_ LVEF ≤40% & inducible VT/VF; _life expectancy must be_ >_1 y;_

More recently, for niCMP ICD ↓ SCD but not overall mortality (_NEJM_ 2016;375:1221);

Consider if unexplained syncope + DCM, or if HCM, ARVC, Brugada, sarcoid, LQTS, Chagas, or congenital heart disease if risk for SCD;

Pts with recent MI: wearable vest ? ↓ death (_NEJM_ 2018;379:1205)

• **Risks:** inapprop shock in ~15–20% at 3 y (commonly d/t misclassified SVT); infxn; lead fx

• ICD discharge: ✔ device to see if approp; 排除 ischemia; 6-mo driving ban (✔ state law)

• MRI: older systems may be OK (_NEJM_ 2017;377:2555); may need to reprogram prior to MRI

### Device infection (_JAMA_ 2012;307:1727; _NEJM_ 2012;367:842 & 2019;380:1895)

• Presents as _pocket infection_ (warmth, erythema, tenderness) and/or _sepsis w_/ _bacteremia_

• ~2% over 5 y; if _S. aureus_ bacteremia, infxn in ≥35%; antibacterial envelope ↓ risk

• TTE/TEE used to help visualize complic. (eg, vegetation), but even ⊖ TEE does not 排除

• Rx: 抗生素; system removal if pocket infxn or GPC bacteremia; ∅ routine 抗生素 prior to inv. proc.
